Knowledge Library

Throughout much of the development in ex vivo gene therapies, Lentiviral vectors have been a preferred vehicle due to their ability to integrate into the host cell genome and infect dividing as well as non-dividing cells. With the continued evolution of CAR-T therapies to include new modalities such as allogeneic and in vivo treatments, flexible …Read More >

For developers involved in AAV therapeutics, three key considerations are critical to successful commercialization: Quality, Quantity, and Speed.  In this webinar, Dr. Jason King demonstrate how OXGENE’s AAV plasmid system together with WuXi ATU’s AAV suspension manufacturing platform delivers higher titers and improved quality compared to industry standard in any serotype, at any scale and …Read More >

In recent years, the demand for cell and gene therapy has increased substantially. The success in gene and cell therapy has also increased demand for plasmid DNA. In supplying the industry with high-quality plasmid DNA, key prominent market challenges are capacity availability, accelerated turnaround time (TAT), and affordability. In this presentation, WuXi Advanced Therapies will …Read More >

The field of gene and cell therapies expand rapidly in the past several years. Lentiviral vectors have been in a great demand as gene carriers in this field, especially for ex vivo gene therapies. However, the large scale lentiviral vector production still remains significant challenges. WuXi Advanced Therapies have experience working with Lentivirus since 2015 …Read More >

In order to promote the public’s awareness of rare diseases and showcase WuXi AppTec’s positive social impact, on Aug. 20, we organized a 3-session webinar series on Spinal Muscular Atrophy, including a fireside chat between Dr. David Chang, CEO of WuXi ATU, and Paulo Fontoura, Global Head and SVP, Neuroscience and Rare Diseases Clinical Development …Read More >